Clinical Trial Update: Almonertinib Vs. Erlotinib/Chemotherapy for Neo-adjuVant Treatment of Stage IIIA-N2 EGFR-mutated NSCLC [Phase 2]

View source ↗

Summary

Phase 2 trial comparing almonertinib to erlotinib or chemotherapy as neoadjuvant treatment for Stage IIIA-N2 EGFR-mutated non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Almonertinib (almonertinib)
• ERLOTINIB (Erlotinib)

Snippet

Sponsor: The First Affiliated Hospital of Guangzhou Medical University | Conditions: Non-Small Cell Lung Cancer Stage IIIA | Phase 2 | Status: UNKNOWN